By Reuters
Share this articleComments
ZURICH (Reuters) - Chinese regulators are speeding up drug approvals, with Roche's <ROG.S> Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies' growth plans.
China's National Drug Administration backed the Swiss drugmaker's Alecensa to treat a kind of lung cancer, called anaplastic lymphoma kinase-, or ALK-positive, less than a year after European and U.S. approvals.
(Reporting by John Miller)
Share this articleComments